DC-HIL/Glycoprotein Nmb Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T Cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
DC-HIL/glycoprotein nmb (Gpnmb) expressed on antigen-presenting cells attenuates T-cell activation by binding to syndecan-4 (SD-4) on activated T cells. Because DC-HIL/Gpnmb is expressed abundantly by mouse and human melanoma lines, we posited that melanoma-associated DC-HIL/Gpnmb exerts similar inhibitory function on melanoma-reactive T cells. We generated small interfering RNA–transfected B16F10 melanoma cells to completely knock down DC-HIL/Gpnmb expression, with no alteration in cell morphology, melanin synthesis, or MHC class I expression. This knockdown had no effect on B16F10 proliferation in vitro or entry into the cell cycle following growth stimulation, but it markedly reduced the growth of these cells in vivo following their s.c. injection into syngeneic immunocompetent (but not immunodeficient) mice. This reduction in tumor growth was due most likely to an augmented capacity of DC-HIL–knocked down B16F10 cells (compared with controls) to activate melanoma-reactive T cells as documented in vitro and in mice. Whereas DC-HIL knockdown had no effect on susceptibility of melanoma to killing by cytotoxic T cells, blocking SD-4 function enhanced the reactivity of CD8+ T cells to melanoma-associated antigens on parental B16F10 cells. Using an assay examining the spread to the lung following i.v. injection, DC-HIL–knocked down cells produced lung foci at similar numbers compared with that produced by control cells, but the size of the former foci was significantly smaller than the latter. We conclude that DC-HIL/Gpnmb confers upon melanoma the ability to downregulate the activation of melanoma-reactive T cells, thereby allowing melanoma to evade immunologic recognition and destruction. As such, the DC-HIL/SD-4 pathway is a potentially useful target for antimelanoma immunotherapy. Cancer Res; 70(14); 5778–87. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 1×
“Packaging of pSIF constructs in pseudoviral particles and their titration were performed according to established protocols (23).”
MethodIwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527 · cited 2×
“for PD-1 (the TCR for PD-L1), B16F10 melanoma cells grew at a rate similar to that in wild-type mice (37), whereas inoculation of melanoma cells into mice overexpressing PD-1 markedly enhanced their growth (38).”
BackgroundResultValenti, R., Huber, V., Filipazzi, P., Pilla, L., Sovena, G., Villa, A., Corbelli, A., Fais, S., Parmiani, G., & Rivoltini, L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1819 · Cited by 493
Tomihari, M., Hwang, S., Chung, J., Cruz Jr., P. D., & Ariizumi, K. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00830.x · Cited by 84
Self-citation
Cited by
Engineering exosomes as refined biological nanoplatforms for drug delivery
Luan, X., Sansanaphongpricha, K., Myers, I., Chen, H., Yuan, H., & Sun, D. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.12 · Cited by 1,163
Design strategies and application progress of therapeutic exosomes
Liu, C., & Su, C. (2019) · Theranostics · doi:10.7150/thno.30853 · Cited by 415
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments
Taylor, D. D., & Gercel-Taylor, C. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-010-0234-8 · Cited by 383
Rose, A. A. N., Annis, M. G., Dong, Z., Pepin, F., Hallett, M., Park, M., & Siegel, P. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012093 · Cited by 219
“Recently, an alternate mechanism, involving GPNMB/OA-mediated suppression of T-cell activation, has been proposed to explain how GPNMB/OA can promote the growth of melanoma tumors [25].”
BackgroundInfluentialThe Role of GPNMB in Inflammation
Saade, M., Araujo de Souza, G., Scavone, C., & Kinoshita, P. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674739 · Cited by 216
“A study showed that GPNMB can attenuate the activation of T cells that are activated via syndecan-4, allowing the evasion of melanoma cells for immunological recognition and destruction (40), whereas the blockade of GPNMB by antibodies restores the integrity of T cells, attenuates tumor TABLE 2 | Outcome of models tha…”
Background
Metadata
- Authors
- Tomihari, M., Chung, J.-S., Akiyoshi, H., Cruz, P. D., & Ariizumi, K.
- Venue
- Cancer Research
- Published
- 2010-07-14
- Volume
- 70
- Issue
- 14
- Pages
- 5778-5787
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2037300553
- Cited by
- 83
- References
- 7
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DC-HIL/Glycoprotein Nmb Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-2538
- The paper
- Tomihari, M., Chung, J.-S., Akiyoshi, H., Cruz, P. D., & Ariizumi, K. (2010). DC-HIL/Glycoprotein Nmb Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-2538
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.